Noxopharm (ASX:NOX) receives approval from U.S. FDA for Veyonda
- Clinical drug development company Noxopharm (NOX) has received approval from the U.S. Food and Drug Administration for its Veyonda cancer treatment
- This approval will see Noxopharm begin a study in using Veyonda to treat cancerous cells found in fat, blood and muscle tissue
- Chief Medical Officer Gisela Mautner said the drug met the FDA's very high standard as a safe and well-tolerated drug
U.S. FDA approval ahead of Veyonda Phase 1b study
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $19.58M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 334 | 6.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 30000 | 1 |
View Market Depth
| Last trade - 09.34am 14/06/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable